BioPharmSignal logoBioPharmSignal

Biotech News

Milestone® Pharmaceuticals to Present at the TD Cowen 46th Annual Health Care Conference

Milestone Pharmaceuticals Inc. (MIST)Milestone Pharmaceuticals Inc.Conference / presentation

MONTREAL and CHARLOTTE, N.C., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Milestone ® Pharmaceuticals Inc. (Nasdaq: MIST) today announced that Amit Hasija, Chief Financial Officer, and Lorenz Muller, Chief Commercial Officer, will present at the TD Cowen 46th Annual Health Care Conference, to take place

Related news

MISTMilestone Pharmaceuticals Inc.2026-05-14 12:30 EST

Milestone Pharmaceuticals to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ

MISTMilestone Pharmaceuticals Inc.2026-04-07 12:30 EST

Milestone Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference

CVRXCVRx2026-05-20 20:30 EST

CVRx to Present at the William Blair 46th Annual Growth Stock Conference

CVRXCVRx2026-07-28 12:30 EST

CVRx to Present at Canaccord Genuity's 46th Annual Growth Conference

LXRXLexicon Pharmaceuticals2026-05-28 12:30 EST

Lexicon Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference

LXRXLexicon Pharmaceuticals2026-05-12 12:30 EST

Lexicon Pharmaceuticals to Present at the 4th Annual H.C. Wainwright BioConnect Investor Conference

SGMTSagimet Biosciences2026-08-04 11:00 EST

Sagimet Biosciences to Participate in the Canaccord Genuity 46th Annual Growth Conference

VANIVivani Medical2026-07-14 20:03 EST

Vivani Medical to Present at the Emerging Growth Conference on July 15, 2026

RYTMRhythm Pharmaceuticals2026-05-29 12:00 EST

Rhythm Pharmaceuticals Announces Seven Abstracts Accepted for Presentation at ENDO 2026

RYTMRhythm Pharmaceuticals2026-05-06 12:00 EST

Rhythm Pharmaceuticals Announces Participation in Upcoming Bank of America Global Healthcare Conference

View all latest news

Milestone Pharmaceuticals Inc.

Self-Administered Cardiac Rescue Therapy Milestone Pharmaceuticals develops rapid-onset nasal therapies for episodic cardiovascular conditions that patients can administer outside a medical setting. CARDAMYST CARDAMYST is an FDA-approved etripamil nasal spray that adults can self-administer to convert symptomatic paroxysmal...

Recent company news

MISTMilestone Pharmaceuticals Inc.2026-08-21 12:00 EST

Milestone Pharmaceuticals Initiates Pivotal Phase 3 Trial of Etripamil Nasal Spray for Self-Administered Treatment of Atrial Fibrillation with Rapid Ventricular Rate (AFib-RVR)

MISTMilestone Pharmaceuticals Inc.2026-08-12 11:08 EST

Milestone Pharmaceuticals Announces Second Quarter 2026 Financial Results and Provides Corporate Update

MISTMilestone Pharmaceuticals Inc.2026-08-04 20:01 EST

Milestone Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 12, 2026

MISTMilestone Pharmaceuticals Inc.2026-07-03 01:30 EST

Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MISTMilestone Pharmaceuticals Inc.2026-05-14 12:30 EST

Milestone Pharmaceuticals to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ

Stock data

Close
1.06 USD
Market cap
164.34M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States